NEW YORK, Feb. 10, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou” or the “Company”). CRBU and certain officers and directors. The Class Action, filed in the United States District Court for the Northern District of California and Filed at 23-cv-00609, is brought on behalf of a class consisting of all persons and entities other than the defendants who purchased or have otherwise acquired: (a ) Caribou common stock pursuant to and/or traceable to the offering documents (defined below) issued in connection with the Company’s initial public offering (the “IPO” or the “Offering”) on or about July 23, 2021 ) were issued; and/or (b) Caribou Securities between July 23, 2021 and December 9, 2022, both dates inclusive (the “Collection Period”). Plaintiff is pursuing claims against Defendants under the Securities Act of 1933 (the “Securities Act”) and the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who (a) purchased or otherwise acquired Caribou common stock pursuant to and/or traceable to the offering documents issued in connection with the Company’s IPO and/or (b) Caribou securities during the Class Period, you have until April time November 2023 to ask the court to appoint you as lead plaintiff for the class. A copy of the complaint is available at www.pomerantzlaw.com. To discuss this promotion, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, ext. 7980. Persons inquiring by email are asked to provide their mailing address, telephone number and the number of shares purchased.

[Click here for information about joining the class action]

Caribou is a clinical-stage biopharmaceutical company developing genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. The company develops products…